Information on EC 3.4.21.98 - hepacivirin

New: Word Map on EC 3.4.21.98
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Flaviviridae

EC NUMBER
COMMENTARY hide
3.4.21.98
-
RECOMMENDED NAME
GeneOntology No.
hepacivirin
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
-
-
-
-
CAS REGISTRY NUMBER
COMMENTARY hide
149885-80-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
genotype 4a
-
-
Manually annotated by BRENDA team
strain H
-
-
Manually annotated by BRENDA team
strain J
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
2-Naph-3Pya-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Cit-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Cit-Orn-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-hArg-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Lys-AcLys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Lys-Arg-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Lys-Cit-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Lys-hArg-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Lys-Orn-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Orn-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
2-Naph-Orn-Orn-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
4-(4-dimethylaminophenylazo)benzoyl-DEMEECASHE-5-(2-aminoethylamino)-1-sulfonic acid + H2O
4-(4-dimethylaminophenylazo)benzoyl-DEMEEC + ASHE-5-(2-aminoethylamino)-1-sulfonic acid
show the reaction diagram
-
-
-
?
7-methoxycoumarin-4-acetyl-DEMEECASHLPYK-(epsilon-NHCOCH3) + H2O
7-methoxycoumarin-4-acetyl-DEMEEC + ASHLPYK-(epsilon-NHCOCH3)
show the reaction diagram
-
-
-
?
7-methoxycoumarin-4-acetyl-EDASTPCSGSN-(4-nitro)Phe + H2O
7-methoxycoumarin-4-acetyl-EDASTPC + SGSN-(4-nitro)Phe
show the reaction diagram
-
-
-
?
9-fluorenylmethyloxycarbonyl-YQEFDEMEECASHLPYIEQG + H2O
9-fluorenylmethyloxycarbonyl-YQEFDEMEEC + ASHLPYIEQG
show the reaction diagram
-
-
-
?
Ac-Aib-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Aoc-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-psi-(COO)Ala-Ser-Lys(DABCYL)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-psi-[COO]Ala-Ser-Lys(DABCYL)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-PSI[COO]Ala-Ser-Lys(DABCYL) + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Asp-Glu-Glu(EDANS)-Glu-Glu-AlgPSI[COO]-Ala-Ser-Lys(DABCYL)-amide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Asp-Glu-Lys(TAMRA)-Glu-Glu-AbuPSI[COO]-Ala-Ser-Lys(QSY-7)-amide + H2O
?
show the reaction diagram
-
efficient substrate for the protease
-
-
?
Ac-Cha-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Chg-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-DED-(EDANS)-EEAbupsi[COO]ASK(Dabcyl)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-DEEMECASHLPYK-NH2 + H2O
Ac-DEEMEC + ASHLPYK-NH2
show the reaction diagram
-
-
-
?
Ac-DPNRKR-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-DTEDVVP(Nva)-O-4-PAP + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-DTEDVVP(Nva)-O-4-phenylazophenyl ester + H2O
?
show the reaction diagram
-
-
-
?
Ac-EMEECASHLP + H2O
Ac-EMEEC + ASHLP
show the reaction diagram
-
-
-
?
Ac-FASGKR-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-KPGLKR-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-L-Asp-L-Glu-L-Asp-(EDANS)-L-Glu-L-Glu-alpha-aminobutyric acid-PSI[COO]-L-Ala-L-Ser-L-Lys-(DABCYL)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-3Pya-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-4Pya-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-aPhe-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-Cit-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-Gln-Tyr-Thr-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-hArg-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-nPhe-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Leu-Orn-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-LQYTKR-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Nle-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Nva-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-Tbg-Lys-Lys-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Ac-YQEFDEMEECAS + H2O
Ac-YQEFDEMEEC + AS
show the reaction diagram
-
-
-
?
Ac-YQEFDEMEECASH + H2O
Ac-YQEFDEMEEC + ASH
show the reaction diagram
-
-
-
?
Ac-YQEFDEMEECASHL + H2O
Ac-YQEFDEMEEC + ASHL
show the reaction diagram
-
-
-
?
Ac-YQEFDEMEECASHLP + H2O
Ac-YQEFDEMEEC + ASHLP
show the reaction diagram
-
-
-
?
acetyl-Asp-Glu-Asp-(5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid)-Glu-Glu-(alpha-aminobutyryl)PSI[COO]Ala-Ser-Lys-(4-[[4'-(dimethylamino)phenyl]azo]-benzoic acid)-NH2 + H2O
?
show the reaction diagram
-
-
-
?
acetyl-DED(EDANS)EEalpha-aminobutyryl-psi(COO)ASK(DABCYL)-NH2 + H2O
?
show the reaction diagram
acetyl-DEMEECASHLPYL-(epsilon-NHCOCH3) + H2O
acetyl-DEMEEC + ASHLPYL-(epsilon-NHCOCH3)
show the reaction diagram
-
-
-
?
acetyl-DTEDVVCCSMSYTWTGK + H2O
?
show the reaction diagram
-
-
-
-
?
acetyl-DTEDVVP-norvaline-O-4-phenylazophenol + H2O
?
show the reaction diagram
-
-
-
?
anthraniloyl-DDIVP-Abu[C(O)-O] AMY(3-NO2)-TW-OH + H2O
?
show the reaction diagram
-
-
-
-
?
anthranilyl-DDIVPAbu[C(O)-O]AMY(3-NO2)TW-OH + H2O
?
show the reaction diagram
Boc-Gly-Arg-Arg-AMC + H2O
?
show the reaction diagram
-
-
-
-
?
Boc-RVRR-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
Bz-nKRR-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
Bz-Nle-Lys-Arg-Arg-AMC + H2O
?
show the reaction diagram
-
-
-
-
?
CARDIF + H2O
?
show the reaction diagram
caspase recruitment domain adaptor-inducing IFN-beta (Cardif) + H2O
?
show the reaction diagram
-
-
-
-
?
CD8-1 + H2O
?
show the reaction diagram
-
synthetic substrate consisting of lymphocyte surface antigen CD8alpha, an enzyme cleavage site and a membrane anchor featuring an endoplasmic reticulum retention sequence
-
-
?
DCSTPCSGSW-NH2 + H2O
DCSTPC + SGSW-NH2
show the reaction diagram
-
-
-
?
DDICPCSMSYTW-OH + H2O
DDICPC + SMSYTW-OH
show the reaction diagram
-
-
-
?
DEMEECASHLPYK + H2O
DEMEEC + ASHLPYK
show the reaction diagram
-
-
-
?
DEMEECSQHLPYI + H2O
DEMEEC + SQHLPYI
show the reaction diagram
-
-
-
?
DTEDVVCCSMSYTWTGK + H2O
DTEDVVCC + SMSYTWTGK
show the reaction diagram
-
-
-
?
EAGDDIVPCSMSYTWTGA-OH + H2O
EAGDDIVPC + SMSYTWTGA-OH
show the reaction diagram
-
-
-
?
EAGDNIVPCSMSYTWTGA-OH + H2O
EAGDNIVPC + SMSYTWTGA-OH
show the reaction diagram
-
-
-
?
EAGNDIVPCSMSYTWTGA-OH + H2O
EAGNDIVPC + SMSYTWTGA-OH
show the reaction diagram
-
-
-
?
EAGNNIVPCSMSYTWTGA-OH + H2O
EAGNNIVPC + SMSYTWTGA-OH
show the reaction diagram
-
-
-
?
ECTTPCSGSWIRD + H2O
ECTTPC + SGSWIRD
show the reaction diagram
-
-
-
?
EDVV-4-aminobutyric acid-CSMSY-NH2 + H2O
EDVV-4-aminobutyric acid-C + SMSY-NH2
show the reaction diagram
-
-
-
?
EDVV-4-aminobutyryl-CSMSY + H2O
EDVV-4-aminobutyryl-C + SMSY
show the reaction diagram
EDVV-Abu-CSMSY + H2O
?
show the reaction diagram
-
-
-
-
?
EDVVPCSMSYN + H2O
?
show the reaction diagram
-
-
-
?
Glu-Asp-Val-Val-4-aminobutyryl-Cys-p-nitroanilide + H2O
Glu-Asp-Val-Val-4-aminobutyryl-Cys + 4-nitroaniline
show the reaction diagram
-
-
-
?
hepatitis C virus polyprotein + H2O
?
show the reaction diagram
hepatitis virus C polyprotein + H2O
?
show the reaction diagram
-
maturation of the viral polyprotein
-
-
-
Hepatitis virus C polyprotein NS5A/NS5B + H2O
?
show the reaction diagram
human mitochondrial antiviral signaling protein + H2O
?
show the reaction diagram
-
-
-
-
?
interferon promoter stimulator-1 + H2O
?
show the reaction diagram
-
protease domain of NS3-4A is sufficient for targeting and cleavage. Targeted cleavage inhibits downstream signaling to interferon regulatory factor-3 and nuclear factor kappaB
-
-
?
MAVS/IPS-1 + H2O
?
show the reaction diagram
-
-
-
-
?
mitochondrial antiviral signaling protein + H2O
?
show the reaction diagram
-
i.e. MAVS, cleavage at Cys-508
-
-
?
myelin basic protein + H2O
?
show the reaction diagram
-
-
-
-
?
non-structural protein NS5B of hepatitis C virus + H2O
? + DDIVPC-OH
show the reaction diagram
NS5A/5B + H2O
?
show the reaction diagram
-
-
-
-
?
NS5A/B polyprotein + H2O
?
show the reaction diagram
-
-
-
-
?
NS5AB polyprotein + H2O
?
show the reaction diagram
-
-
-
-
?
o-aminobenzoyl (Abz)-L-Asp-L-Asp-L-Ile-L-Val-L-Pro-L-Cys-L-Ser-L-Met-L-Ser-L-Tyr(3-NO2)-L-Thr-NH2 + H2O
?
show the reaction diagram
-
i.e. IQGS-1, internally quenched fluorogenic substrate
-
-
?
peroxidase GPx8 + H2O
?
show the reaction diagram
-
-
membrane-associated peroxidase GPx8 is a cellular substrate of the hepatitis C virus NS3-4A protease. Cleavage by NS3-4A occurs at Cys11, removing the cytosolic tip of GPx8, and is observed in different experimental systems as well as in liver biopsies from patients with chronic HCV
-
?
precursor polyprotein of hepatitis C virus + H2O
?
show the reaction diagram
-
-
-
-
?
Pyr-RTKR-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
RetS1 peptide substrate + H2O
?
show the reaction diagram
SEAP-1 + H2O
?
show the reaction diagram
-
synthetic substrate consisting of alkaline phosphatase, an enzyme cleavage site and a membrane anchor featuring an endoplasmic reticulum retention sequence
-
-
?
succinyl-DEMEECASHPYPY-NH2 + H2O
succinyl-DEMEEC + ASHPYPY-NH2
show the reaction diagram
-
-
-
?
succinyl-EDVVPCSMYSTW-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Toll-IL-1 receptor domain-containing adaptor inducing interferon-beta + H2O
?
show the reaction diagram
-
-
-
-
?
TRIF + H2O
?
show the reaction diagram
-
-
-
-
?
viral polyprotein + H2O
?
show the reaction diagram
Z-RR-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
CARDIF + H2O
?
show the reaction diagram
caspase recruitment domain adaptor-inducing IFN-beta (Cardif) + H2O
?
show the reaction diagram
-
-
-
-
?
hepatitis C virus polyprotein + H2O
?
show the reaction diagram
hepatitis virus C polyprotein + H2O
?
show the reaction diagram
-
maturation of the viral polyprotein
-
-
-
mitochondrial antiviral signaling protein + H2O
?
show the reaction diagram
-
i.e. MAVS, cleavage at Cys-508
-
-
?
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
KKGSVVIVGRIVLSCK
-
-
KKGSVVIVGRIVLSGK
KKGSVVIVGRIVLSGKPAIIPKK
-
NS-4A cofactor
additional information
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Zinc
-
His149 may be an integral part of zinc coordination, may have a structural rather than a catalytic role, effects on protein folding or post-folding stability
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
((1R,2S)-1-((2S,4S)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(ethyl)phosphinic acid
-
-
((1R,2S)-1-((2S,4S)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(methyl)phosphinic acid
-
-
(-)-epicatechin-3-O-gallate
-
-
(-)-epigallocatechin-3-O-gallate
-
-
(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclobutane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide
-
-
(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclohexane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide
-
-
(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclopentane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide
-
-
(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclopropane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide
-
-
(10R,13R)-N-(1-[[(2-[[(1R)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10-cyclohexyl-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide
-
-
(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-oxo-2,7-dioxa-8-thia-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide 8,8-dioxide
-
-
(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2,7-dioxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide
-
-
(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide
-
-
(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide
-
-
(11R,14R)-N-(1-[[(2-[[(1R)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-cyclohexyl-9,12-dioxo-2-oxa-10,13-diazabicyclo[14.3.1]icosa-1(20),16,18-triene-14-carboxamide
-
-
(11S,14S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-cyclohexyl-9,12-dioxo-1,10,13,17-tetraazabicyclo[14.2.1]nonadeca-16(19),17-diene-14-carboxamide
-
-
(11Z,13aR,15aS)-N-(cyclopropylsulfonyl)-2-([7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy)-15-oxo-1,2,3,7,8,9,10,12a,13,14,15,15a-dodecahydrocyclopropa[f]pyrrolo[1,2-b][1,2,5]thiadiazacyclotetradecine-13a(6H)-carboxamide 5,5-dioxide
-
most potent inhibitor of the series with sulfonamide linkage. The microsomally predicted clearance numbers is 0.17/0.7 L/h/kg (h/r)
(11Z,13aR,15aS)-N-(cyclopropylsulfonyl)-2-([7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy)-5,15-dioxo-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-13aH-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxamide
-
inhibitor with proline amide linkage, slightly more potent than inhibitors with sulfonamide linkage. The microsomally predicted clearance number is 0.17/0.82 L/h/kg (h/r)
(1R)-1-([(4R)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]heptanoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl]amino)-2-ethenylcyclopropanecarboxylic acid
(1R)-2-but-3-en-1-yl-1-[[(4R)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]hept-6-enoyl]-4-(quinolin-4-yloxy)-L-prolyl]amino]cyclopropanecarboxylic acid
-
-
(1R,12E,19S,22S)-19-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,17,20-trioxo-2,16-dioxa-4,18,21-triazatetracyclo[19.2.1.14,7.06,11]pentacosa-6,8,10,12-tetraene-22-carboxamide
-
-
(1R,12E,20S,23S)-20-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,20S,23S)-20-cyclohexyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,20S,23S)-20-cyclopentyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,20S,23S)-20-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,20S,23S)-20-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,20S,23S)-20-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-4-methyl-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatricyclo[20.2.1.06,11]pentacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,20S,23S)-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]-carbonyl]-2-vinylcyclopropyl)-20-(1-methylcyclohexyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,20S,23S)-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]-carbonyl]-2-vinylcyclopropyl)-20-isopropyl-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide
-
-
(1R,12E,21S,24S)-21-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6,8,10,12-tetraene-24-carboxamide
-
-
(1R,12E,22S,25S)-22-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,20,23-trioxo-2,19-dioxa-4,21,24-triazatetracyclo[22.2.1.14,7.06,11]octacosa-6,8,10,12-tetraene-25-carboxamide
-
-
(1R,20S,23S)-20-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10-triene-23-carboxamide
-
-
(1R,20S,23S)-20-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10-triene-23-carboxamide
-
-
(1R,21S,24S)-21-(tert-butoxymethyl)-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
-
-
(1R,21S,24S)-21-cyclohexyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
-
-
(1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6,8,10-triene-24-carboxamide
-
-
(1R,21S,24S)-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]-carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-21-(1-methylcyclohexyl)-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6,8,10-triene-24-carboxamide
-
-
(1R,2S)-1-[([(1R,2R,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopentyl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid
-
-
(1R,2S)-1-[([(1R,4R)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid
-
-
(1R,2S)-1-[([(1R,4R)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid
-
-
(1R,2S)-1-[([(1S,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid
-
-
(1R,2S)-1-[([(1S,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid
-
-
(1R,2S)-1-[[(1R,2R,4S)-2-((S)-1-cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
-
(1R,2S)-1-[[(1R,2R,4S)-2-((S)-1-tert-butylcarbamoyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
-
(1R,2S)-1-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyldimethylcarbamoyl-methyl)-carbamoyl]-2,2-dimethylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
-
(1R,2S)-1-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexylmethylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
-
(1R,2S)-1-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexylmethylcarbamoyl-methyl)-methyl-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
-
(1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl](methyl)carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylic acid
-
-
(1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylic acid
-
-
(1R,5S)-3-(N-[[(1S)-1-cyclohexyl-2-cyclopropyl-2-oxoethyl]carbamoyl]-3-methyl-L-valyl)-N-[1-(cyclopropylamino)-1,2-dioxohept-6-yn-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1R,5S)-3-[2(S)-[[[[1-[(1-azetidinylsulfonyl)methyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-3-[2(S)-[[[[1-[[[cyclobutyl(methyl)amino]sulfonyl]methyl]cyclohexyl]amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyll]-butyl]-3-[2(S)-[[[[1-[[(dimethylamino)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[(2S)-2-[[[[1-[1(R)-[(dimethylamino)sulfonyl]ethyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyll-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[(2S)-[[[[1-[1(S)-[(dimethylamino)sulfonyl]ethyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyll-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-(2-cyclopropyl-1,1-dioxido-5(R)-isothiazolidinyl)cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[(2-fluoro-1,1-dimethylethyl)methylamino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]-hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[(cyclopropylmethyl)methylamino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[cyclopropyl(1-methylethyl)amino]-sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[cyclopropyl(methyl)amino]sulfonyl]-methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[ethyl(methyl)amino]sulfonyl]methyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[3,3-dimethyl-2(S)-[[[[1-[(4-morpholinylsulfonyl)-methyl]cyclohexyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[3,3-dimethyl-2(S)-[[[[1-[[(methylamino)sulfonyl]-methyl]cyclohexyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[3,3-dimethyl-2(S)-[[[[1-[[[methyl(1-me5thylethyl)-amino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-pemtyl]-3-[2(S)-[[[[1-[[[cyclopropyl(methyl)amino]sulfonyl]-methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[3-(cyclopropylamino)-1(S)-(2-cyclopropylethyl)-2,3-dioxopropyl]-3-[2(S)-[[[[1-[[[cycloppropyl(methyl)-amino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]-hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[3-(cyclopropylamino)-1(S)-(cyclopropylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[[1-[[[cyclopropyl(methyl)-amino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]-hexane-2(S)-carboxamide
-
-
(1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide
-
Boceprevir: EC50 and EC90 values, determined in a bicistronic, subgenomic, cell-based replicon assay run over 72 h using Huh-7 hepatoma cells, are 200 and 400 nM, respectively. Preclinical, metabolism and pharmacokinetics data are very promising. Currently ongoing phase II clinical trials demonstrate the compound to be well tolerated
(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide
-
-
(1S,5R)-6,6-dichloro-3-[cyclohexyl[[[(1,1-dimethylethyl)amino]carbonyl]amino]acetyl]-N-[1-[1,2-dioxo-2-(2-propenylamino)ethyl]butyl]-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide
-
-
(1S,5R)-N-((S)-5-cyclopropyl-1-(cyclopropylamino)-1,2-dioxopentan-3-yl)-3-((S)-2-(3-(1-((N-cyclopropyl-N-methylsulfamoyl)methyl)cyclohexyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(1-amino-5,5-difluoro-1,2-dioxoheptan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(1-amino-5,5-difluoro-1,2-dioxohexan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(1-amino-6,6,6-trifluoro-1,2-dioxohexan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(1-amino-7,7,7-trifluoro-1,2-dioxoheptan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(4-amino-1-((1s,3S)-3-hydroxycyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(4-amino-1-(1-fluorocyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(4-amino-1-(1-hydroxycyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(4-amino-1-(2,2-difluorocyclopropyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(4-amino-1-(3,3-difluorocyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(1S,5R)-N-(5-amino-1,1,1-trifluoro-4,5-dioxopentan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
-
-
(2-(3-((12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo-(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid
-
-
(2-(3-((12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo-(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid tert-butyl ester
-
-
(2-(3-((12-cyclohexyl-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,-13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid tert-butyl ester
-
-
(2-(3-((3-cyclohexyl-2,5-dioxo-12-oxa-1,4-diazatricyclo(11.5.3.016,20)henicosa-13(21),14,16(20)-triene-18-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid
-
-
(2-(3-((3-cyclohexyl-2,5-dioxo-12-oxa-1,4-diazatricyclo(11.5.3.016,20)henicosa-13(21),14,16(20)-triene-18-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid tert-butyl ester
-
-
(2R)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2,10-dioxa-13-azatricyclo[15.2.2.13,7]docosa-1(19),3(22),4,6,17,20-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2R)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-1(19),3(22),4,6,17,20-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2R)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[16.2.2.13,7]tricosa-1(20),3(23),4,6,18,21-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2R)-2-(acetylamino)-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid
-
-
(2R)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-2-phenylquinazolin-4-yl)oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-8-methyl-2-phenylquinazolin-4-yl)oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-8-methylquinazolin-4-yl)oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-2-(4-methoxyphenyl)-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-8-methyl-2-(6-methylpyridin-2-yl)quinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-8-methyl-2-(pyridin-3-yl)quinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-8-methyl-2-(pyridin-4-yl)quinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-2-[[2-(morpholin-4-yl)quinazolin-4-yl]oxy]-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-4,14-dioxo-2-[(2-phenylquinazolin-4-yl)oxy]-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2R,4S,7S,14Z)-7-tert-butyl-N-[(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl]-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-etheno-2,5-methanopyrido[2,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide
-
-
(2R,6R,12Z,13aR,14S,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14-carboxylic acid
-
-
(2R,6S,10E,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
(2R,6S,10E,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-5,16-dioxo-2-(quinolin-4-yloxy)-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,10Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,13aS,14aR,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine
-
-
(2R,6S,12Z,14aR,16aS)-2-[(8-chloro-2-ethoxyquinolin-4-yl)oxy]-6-[[(cyclopentyloxy)carbonyl]amino]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-([7-methoxy-2-[2-(methylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxyquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[(4-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[2-(1H-imidazol-1-yl)-7-methoxyquinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(1H-pyrazol-1-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(1H-pyrrol-1-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(4-methyl-1H-pyrazol-1-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,12Z,14aR,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-[(5-ethoxythieno[3,2-b]pyridin-7-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(2R,6S,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxohexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
(2S)-([N-[3-([[(10S,13S)-10-cyclohexyl-8,11-dioxo-2,7-dioxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-trien-13-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2S)-([N-[3-([[(3S,18S)-18-cyclohexyl-16,19-dioxo-3,4-dihydro-1H-7,2-(epoxyheptanoiminoethano)isoquinolin-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2S)-([N-[3-([[(3S,6S)-6-cyclohexyl-5,8-dioxo-4,7-diazabicyclo[14.3.1]icosa-1(20),16,18-trien-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2S)-([N-[3-([[(7R,9S,12S)-12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2S)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[17.2.2.13,7]tetracosa-1(21),3(24),4,6,19,22-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid
-
-
(2S)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid
-
-
(2S)-2-[([(1R,4R)-2-[[(1R)-1-[[(1R)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]butanoic acid
-
-
(2S)-2-[[(2-[[(1S)-1-(methoxycarbonyl)-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid
-
-
(2S)-2-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid
-
-
(2S)-2-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid
-
-
(2S)-2-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid
-
-
(2S)-[([[3-([[(6S,8S,9R,10S,13S)-13-cyclohexyl-12,15-dioxo-2,7,23-trioxa-11,14-diazatetracyclo[15.3.1.16,9.18,11]tricosa-1(21),17,19-trien-10-yl]carbonyl]amino)-2-oxohexanoyl]amino]acetyl)amino](phenyl)ethanoic acid
-
-
(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-([7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinazolin-4-yl]oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(3-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxyquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-2-[[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]oxy]-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-4,14-dioxo-2-([2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinazolin-4-yl]oxy)-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
-
-
(2S,3aR,11Z,12aS,13aR,15aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-8-methyl-2-phenylquinazolin-4-yl)oxy]-4,15-dioxo-1,2,3,3a,4,5,6,7,8,9,10,12a,13,14,15,15a-hexadecahydro-13aH-cyclopenta[c]cyclopropa[g][1,6]diazacyclopentadecine-13a-carboxamide
-
-
(2S,3aR,11Z,12aS,13aR,15aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-4,15-dioxo-1,2,3,3a,4,5,6,7,8,9,10,12a,13,14,15,15a-hexadecahydro-13aH-cyclopenta[c]cyclopropa[g][1,6]diazacyclopentadecine-13a-carboxamide
-
-
(2S,4S)-1-((S)-2-((R)-2-cyclohexyl-2-(prop-1-en-2-ylamino)acetamido)-3,3-dimethylbutanoyl)-N-((1S,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-phenylpyrrolidine-2-carboxamide
-
-
(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,15-trioxo-1,4,10-triazacyclopentadecane-5-carboxamide
-
-
(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,16-trioxo-1,4,10-triazacyclohexadecane-5-carboxamide
-
-
(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,17-trioxo-1,4,10-triazacycloheptadecane-5-carboxamide
-
-
(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,18-trioxo-1,4,10-triazacyclooctadecane-5-carboxamide
-
-
(2S,6S,12Z,13aS,14aR,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid
-
-
(3R)-2-[2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-N-[1-(cyclobutylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide
-
comparison of binding affinity with human neutrophil elastase, selectivity of 420
(3R)-2-[2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-N-[1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide
-
comparison of binding affinity with human neutrophil elastase, selectivity of 35
(3R)-2-[[(tert-butylcarbamoyl)amino](cyclohexyl)acetyl]-N-[1-(cyclobutylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide
-
-
(3R)-2-[[(tert-butylcarbamoyl)amino](cyclohexyl)acetyl]-N-[1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide
-
-
(3R,12S,16R,17aS)-12-[(tert-butoxycarbonyl)amino]-16-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-1,13-dioxohexadecahydro-1H-pyrrolo[1,2-a][1,4]diazacyclopentadecine-3-carboxylic acid
-
-
(3S)-3-[(7R,9S,12R)-9-[(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-12-yl]cyclohexanecarboxylic acid
-
-
(3S,12S,16R,17aS)-12-[(tert-butoxycarbonyl)amino]-16-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-1,13-dioxohexadecahydro-1H-pyrrolo[1,2-a][1,4]diazacyclopentadecine-3-carboxylic acid
-
-
(3S,18S)-18-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-16,19-dioxo-3,4-dihydro-1H-7,2-(epoxyheptanoiminoethano)isoquinoline-3-carboxamide
-
-
(3S,6S)-6-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,8-dioxo-4,7-diazabicyclo[14.3.1]icosa-1(20),16,18-triene-3-carboxamide
-
-
(4-acetylphenoxy)acetic acid
-
-
(4-aminophenyl)(2-aminopyridin-3-yl)methanone
-
-
(4-aminophenyl)(phenyl)methanone
-
-
(4-methoxyphenyl)(1H-pyrrol-2-yl)methanone
-
-
(4R)-4-[[(2S)-2-(acetylamino)-3-carboxypropanoyl]amino]-5-[(1-[[(1R)-1-([(2S,4R)-4-(benzyloxy)-2-[(2-[[(1S)-1-phenylethyl]carbamoyl]-2-propylhydrazino)carbonyl]pyrrolidin-1-yl]carbonyl)-2-methylpropyl]carbamoyl]-2-methylbutyl)amino]-5-oxopentanoic acid
-
noncovalent binding to enzyme active site, 50% inhibition at 0.000078 mM
(4R,6S,7Z,15S,17S)-17-[((7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl)oxy)methyl]-13-methyl-N-[(1-methylcyclopropyl)sulfonyl]-2,14-dioxo-1,3,13-triazatricyclo[13.2.0.0-4,6-]heptadec-7-ene-4-carboxamide
-
compound displays high mean clearance of 150 micro per minand mg protein in rat, cynomolgus monkey and human liver microsomes, along with a short half life of less than 10 min
(4R,6S,7Z,15S,17S)-17-[((8-chloro-7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl)oxy)methyl]-13-methyl-N-[(1-methylcyclopropyl)sulfonyl]-2,14-dioxo-1,3,13-triazatricyclo[13.2.0.0-4,6-]heptadec-7-ene-4-carboxamide
-
-
(4R,6S,9S,16E)-9-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-2,8,11-trioxo-3,12-dioxa-1,7,10-triazatetracyclo[16.6.2.14,7.022,26]heptacosa-16,18(26),19,21-tetraene-6-carboxamide
-
-
(4R,6S,9S,16E)-9-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-2,8,11-trioxo-3,12-dioxa-1,7,10-triazatetracyclo[20.3.1.14,7.018,23]heptacosa-16,18,20,22-tetraene-6-carboxamide
-
-
(4S,7S,9R)-4-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2,5-dioxo-10,15-dioxa-3,6-diazatricyclo[14.3.1.16,9]henicosa-1(20),16,18-triene-7-carboxamide
-
-
(5R,7S,10S)-10-cyclopentyl-N-[(1S)-1-[(cyclopropylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-3,9,12-trioxo-N-[(1S)-1-[oxo(prop-2-en-1-ylamino)acetyl]butyl]-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-3,9,12-trioxo-N-[(1S)-1-[oxo[(1-phenylethyl)amino]acetyl]butyl]-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-3,9,12-trioxo-N-[(1S)-1-[oxo[(pyridin-2-ylmethyl)amino]acetyl]butyl]-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclobutylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclopentylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclopropylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-1,6,7,9,10,11,12,14,15,16,17,18-dodecahydro-5H-2,22:5,8-dimethano-4,13,2,8,11-benzodioxatriazacycloicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclopropylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[[(1-methylpropyl)amino](oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,7S,10S)-N-[(1S)-1-[(benzylamino)(oxo)acetyl]butyl]-10-tert-butyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide
-
-
(5R,8S,10R)-5-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-methyl-3,6-dioxo-11,15-dioxa-2,4,7-triazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-8-carboxamide
-
-
(5R,8S,10R)-5-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-3,6-dioxo-11,15-dioxa-2,4,7-triazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-8-carboxamide
-
-
(5R,8S,10R)-5-tert-butyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-3,6-dioxo-2,11,15-trioxa-4,7-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-8-carboxamide
-
-
(5S,8S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5-cyclohexyl-3,6,14-trioxo-4,7,13-triazabicyclo[14.2.2]icosa-1(18),16,19-triene-8-carboxamide
-
-
(5S,8S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5-cyclohexyl-3,6,14-trioxo-4,7,13-triazabicyclo[14.3.1]icosa-1(20),16,18-triene-8-carboxamide
-
-
(5S,8S,10R)-5-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-3,6-dioxo-11,16-dioxa-4,7-diazatricyclo[15.3.1.17,10]docosa-1(21),17,19-triene-8-carboxamide
-
-
(6R,8S,11R)-11-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10,13-dioxo-2,5-dioxa-9,12-diazatricyclo[14.3.1.16,9]henicosa-1(20),16,18-triene-8-carboxamide
-
-
(6R,8S,11S)-11-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10,13-dioxo-2,5-dioxa-9,12-diazatricyclo[13.3.1.16,9]icosa-1(19),15,17-triene-8-carboxamide
-
-
(6R,8S,11S,18E)-11-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3-methyl-4,10,13-trioxo-5,14-dioxa-3,9,12-triazatricyclo[18.3.1.16,9]pentacosa-1(24),18,20,22-tetraene-8-carboxamide
-
-
(6S,11S,20S)-11-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10,13-dioxo-2,5-dioxa-9,12-diazatricyclo[13.3.1.16,9]icosa-1(19),15,17-triene-20-carboxamide
-
-
(6S,8S,9R,10S,13S)-13-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-12,15-dioxo-2,7,23-trioxa-11,14-diazatetracyclo[15.3.1.16,9.18,11]tricosa-1(21),17,19-triene-10-carboxamide
-
-
(7R,9S)-12-(2,3-dihydro-1H-inden-1-yl)-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-15-methyl-11,14-dioxo-2,6-dioxa-10,13,15-triazatricyclo[15.3.1.17,10]docosa-1(21),17,19-triene-9-carboxamide
-
-
(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-18-methoxy-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-18-methyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-19-methyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2-oxa-6-thia-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-6-(phenylsulfonyl)-2-oxa-6,10,13-triazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-12-cyclohexyl-N-[(1S)-1-[[(2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-12-cyclohexyl-N-[(1S)-1-[[[4-(dimethylamino)-2,4-dioxo-3-phenylbutyl]amino](oxo)acetyl]butyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
50% inhibition at 400 nM
(7R,9S,12S)-12-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-12-(1-methylethyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-12-(2-methylpropyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7R,9S,12S)-N-(1-[[(2-[[(S)-cyano(phenyl)methyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide
-
-
(7S,12S,21S)-12-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-21-carboxamide
-
-
(R)-((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(4-methoxybenzyl)phosphinic acid
-
-
(R)-((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(isopropyl)phosphinic acid
-
-
(R)-((1S,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(phenyl)phosphinic acid
-
-
(R)-(4-chlorobenzyl)((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)phosphinic acid
-
-
(R)-4-((S)-2-acetamido-3-carboxypropanamido)-5-((2S,3S)-1-((S)-1-((2S,4R)-4-(benzyloxy)-2-(2-butyl-2-((S)-1-phenylethylcarbamoyl)hydrazinecarbonyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxopentan-2-ylamino)-5-oxopentanoic acid
-
-
-
(R)-benzyl((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)phosphinic acid
-
-
(R)-butyl((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)phosphinic acid
-
-
(S)-((2R,6R,13aS,14S,16aS)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxooctadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)(2-methoxybenzyl)phosphinic acid
-
-
(S)-((2R,6R,13aS,14S,16aS,Z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)(2-methoxybenzyl)phosphinic acid
-
-
(S)-(2-chlorobenzyl)((2R,6R,13aS,14S,16aS)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxooctadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid
-
-
(S)-(2-chlorobenzyl)((2R,6R,13aS,14S,16aS,Z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid
-
-
(S)-2-[[(1R,2R,4S)-2-[(R)-1-[((R)-cyclohexylmethoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid
-
21% inhibition at a concentration of 10 micromol
(S)-2-[[(1R,2R,4S)-2-[(R)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid
-
35% inhibition at a concentration of 10 micromol
(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((R)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid
-
37% inhibition at a concentration of 10 micromol
(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid
-
-
(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid
-
65% inhibition at a concentration of 10 micromol
(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid
-
100% inhibition at a concentration of 10 micromol
(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid
-
-
(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid
-
-
(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexylmethylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-4,4-difluoro-butyric acid
-
-
(S)-2-[[(1R,4R)-2-[(R)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid
-
-
(S)-2-[[(1S,4S)-2-[(R)-1-[((S)-cyclohexyl-methoxycarbonylmethyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid
-
-
(S)-benzyl((2R,6R,13aS,14S,16aS)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxooctadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid
-
-
(S)-benzyl((2R,6R,13aS,14S,16aS,Z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid
-
-
(Z)-(1R,4R,6S,14R,16R)-12-tert-butoxycarbonylamino-16-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,13-dioxo-3,12-diaza-tricyclo[12.3.0. 04, 6]heptadec-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,15R,17R)-13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,15R,17R)-13-tert-butoxycarbonylamino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,15R,17R)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,15R,17S)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo-[13.3.0.04,6]octadec-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,16R,18R)-14-amino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,16R,18R)-14-tert-butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,17R) and (1S,4R,6S,17S)-13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadeca-7,15-diene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,17R,19R)-15-amino-19-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15-diaza-tricyclo[15.3.0.04,6]icos-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,17R,19R)-15-tert-butoxycarbonylamino-19-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15-diaza-tricyclo[15.3.0.04,6]icos-7-ene-4-carboxylic acid
-
-
(Z)-(1R,4R,6S,18R) and (1S,4R,6S,18S)-14-amino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.04,6]nonadeca-7,16-diene-4-carboxylic acid
-
-
1,1-dimethylethyl [1-cyclohexyl-2-[(1S,5R)-6,6-dichloro-2(S)-[[[1-[1,2-dioxo-2-(2-propenylamino) ethyl]butyl]-amino]carbonyl]-3-azabicyclo[3.1.0]hexan-3-yl]-2-oxoethyl]carbamate
-
-
1,1-dimethylethyl [2-[(1S,5R)-2(S)-[[[1-(2-amino-1,2-dioxoethyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hexan-3-yl]-1(S)-cyclohexyl-2-oxoethyl]-carbamate
-
-
1,1-dimethylethyl[1-cyclohexyl-2-[(1S,5R)-6,6-dichloro-2(S)-[[[1-[2-[[2-[[2-(dimethylamino)-2-oxo-1(S)-phenylethyl]amino]-2-oxoethyl]amino]-1,2-dioxoethyl]-butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hexan-3-yl]-2-oxoethyl]carbamate
-
-
1,1-dimethylethyl[2-[(1S,5R)-6,6-dichloro-2(S)-[[ [1-(cyclopropyl-methyl)-3-[[2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl]amino]-2,3-dioxopropyl]-amino]carbonyl]-3-azabicyclo[3.1.0]-hexan-3-yl]-1-cyclohexyl-2-oxoethyl]carbamate
-
-
1,1-dimethylethyl[2-[(1S,5R)-6,6-dichloro-2(S)-[[1-(cyclobutylmethyl)-3-[[2-[[2-(dimethylamino)-2-oxo-1(S)-phenylethyl]amino]-2-oxomethyl]amino]-2,3-dioxopropylamino]carbonyl]-3-azabicyclo[3.1.0]hexan-3-yl]-1(S)-cyclohexyl-2-oxomethyl]carbamate
-
-
1,10-phenanthroline
1,2,3,4-tetrahydroacridin-9-amine
-
inhibitor binding to Zn2+-free enzyme, dissociation constant 0.0017 mM, EC50 value 0.060 mM
1,3,4-tri-O-galloyl-beta-D-glucose
-
from Saxifraga melanocentra
1,3,6-tri-O-galloyl-beta-D-glucose
-
from Terminalia chebula
1-(4-aminophenyl)-2-phenylethane-1,2-dione
-
-
1-([1-[(1,2-diphenylhydrazino)carbonyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-D-prolyl]amino)-2-ethenylcyclopropanecarboxylic acid
-
-
1-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbonyl]-amino)-2-vinyl-cyclopropanecarboxylic acid
-
IC50: 0.0097 mM
1-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid
-
IC50: 0.33 mM
1-([1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid
-
IC50: above 1 mM
1-([1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-phenoxy-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid
-
IC50: above 0.08 mM
1-([4-(3'-Acetylamino-biphenyl-3-yloxy)-1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid
-
IC50: 0.006 mM
1-aminocyclopropane-1-carboxylic acid ketoacid
-
electrophilic and acidic compound
1-aminocyclopropane-1-carboxylic acid ketotetrazole
-
electrophilic and acidic compound
1-aminocyclopropane-1-carboxylic acid pentafluoroethyl ketone
-
electrophilic and non-acidic compound
1-aminocyclopropanecarboxylic acid
-
non-electrophilic and acidic compound
1-benzofuran-2-carboxylic acid
-
-
1-benzothiophene-2-carboxylic acid
-
-
1-methyl-1H-indole-2-carboxylic acid
-
-
1-O-(3-O-galloylgalloyl)-2,3,4-tri-O-galloyl-beta-D-glucose
-
from Saxifraga melanocentra
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-bromo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.025 mM
1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
-
1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
-
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-thiophen-3-yl-pyridin-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: above 0.2 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(3'-nitro-biphenyl-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.006 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(3-bromo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.05 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(3-morpholin-4-yl-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.032 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4'-methoxy-biphenyl-2-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: above 0.2 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4'-methoxy-biphenyl-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.035 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-bromo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.025 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-bromo-phenylsulfanyl)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.04 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-chloro-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.05 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-fluoro-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.1 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-iodo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.01 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(5-chloro-quinolin-8-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.1 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(6-methoxy-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.016 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-chloro-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.002 mM
1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-methoxy-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
-
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-methoxy-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-trifluoromethyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.006 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.009 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(benzothiazol-2-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.02 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(benzothiazol-2-ylsulfanyl)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.02 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(biphenyl-2-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: above 0.2 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(biphenyl-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.006 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(biphenyl-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.035 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(isoquinolin-1-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.008 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(isoquinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.004 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-2,2-diethyl-cyclopropanecarboxylic acid
-
IC50: 0.31 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-2-ethyl-cyclopropanecarboxylic acid
-
IC50: 0.0048 mM
1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid
-
IC50: 0.00063 mM
1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.014 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(pyridin-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.19 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(pyridin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.17 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.005 mM
1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(quinolin-8-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid
-
IC50: 0.25 mM
12-cyclohexyl-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)-methyl)aminooxalyl)butyl)amide
-
50% inhibition at 130 nM
12-tert-butyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)aminooxalyl)butyl)amide
-
50% inhibition at 700 nM
12-tert-butyl-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)-aminooxalyl)butyl)amide
-
50% inhibition at 200 nM
1H-indole-2-carboxylic acid
-
-
2'-[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-5-(1-carboxy-cyclopropylcarbamoyl)-pyrrolidin-3-yloxy]-biphenyl-4-carboxylic acid
-
IC50: above 0.2 mM
2,2,2-trifluoro-1,1-dimethylethyl[2-[(1S,5R)-2(S)-[[[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]-carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hexan-3-yl]-1(S)-cyclohexyl-2-oxoethyl]carbamate
-
-
2,2-Dihydroxy-indan-1,3-dione
-
-
2-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid
-
IC50: above 0.1 mM
2-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid methyl ester
-
IC50: 0.054 mM
2-(3-chlorobenzoyl)benzoic acid
-
-
2-(4-Butyl-phenyl)-2-phenylsulfanyl-indan-1,3-dione
-
IC50: 0.0017 mM
2-(4-carboxybenzoyl)benzoic acid
-
-
2-(4-chlorobenzoyl)-6-(methoxycarbonyl)benzoic acid
-
-
2-(4-chlorobenzoyl)-6-[(dimethylamino)carbonyl]benzoic acid
-
-
2-(4-chlorobenzoyl)benzoic acid
-
-
2-(4-chlorobenzyl)benzoic acid
-
-
2-(4-chlorophenoxy)benzoic acid
-
-
2-(4-fluorobenzoyl)benzoic acid
-
-
2-(4-fluorophenoxy)benzoic acid
-
-
2-(4-hydroxybenzoyl)-4-methylbenzoic acid
-
-
2-(4-hydroxybenzoyl)benzoic acid
-
-
2-(4-hydroxybenzyl)benzoic acid
-
-
2-(4-methoxybenzoyl)benzoic acid
-
-
2-(4-methylbenzoyl)benzoic acid
-
-
2-(4-[3-[1-Carboxy-2-(4-hydroxy-3,5-diiodo-phenyl)-ethylcarbamoyloxy]-propoxy]-benzoyl)-benzoic acid
-
; competitive
2-(4-[3-[1-tert-Butoxycarbonyl-2-(4-hydroxy-3,5-diiodo-phenyl)-ethylcarbamoyloxy]-propoxy]-benzoyl)-benzoic acid tert-butyl ester
-
; competitive
2-(carboxymethyl)-6-(4-chlorobenzoyl)benzoic acid
-
-
2-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbonyl]-amino)-pentanoic acid
-
IC50: 0.53 MM
2-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbony]}-amino)-3-mercapto-propionic acid
-
IC50: 0.14 mM
2-Chloro-6-(4-chloro-benzoyl)-benzoic acid
-
-
2-Hydroxy-2-(1-nitro-ethyl)-indan-1,3-dione
-
-
2-Hydroxy-2-(2-nitro-cyclopentyl)-indan-1,3-dione
-
-
2-Methyl-2-phenylsulfanyl-indan-1,3-dione
-
IC50: 0.0036 mM
2-O-(4-O-galloylgalloyl)-1,3,4-tri-O-galloyl-beta-D-glucose
-
from Rhodiola kirilowii
2-Phenyl-2-phenylsulfanyl-indan-1,3-dione
-
IC50: 0.012 mM
2-Phenylsulfanyl-2-p-tolyl-indan-1,3-dione
-
IC50: 0.0031 mM
2-[1-[1-(1-Carbamoyl-3-methyl-butylcarbamoyl)-2-carboxy-ethylcarbamoyl]-2-cyclohexyl-ethylcarbamoyl]-cyclohexanecarboxylic acid
-
IC50: 0.015 mM, wild-type enzyme, IC50: 0.017 mM, mutant enzyme K136R, IC50: 0.027 mM, mutant enzyme K136M, IC50: 0.05 mM, mutant enzyme K136S, IC50: above 0.3 mM, mutant enzyme R109Q
2-[1-[2-Carboxy-1-(1-ethylcarbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-cyclohexyl-ethylcarbamoyl]-cyclohexanecarboxylic acid
-
IC50: 0.032 mM
2-[4-(3-carboxypropyl)benzoyl]benzoic acid
-
-
2-[4-(trifluoromethyl)benzoyl]benzoic acid
-
-
3,3'-digalloylprocyanidin B2
-
-
3,3'-digalloylproprodelphinidin B2
-
rhodisin
3,4-dichloroisocoumarin
-
0.03 mM, 50% inhibition
3,6-di-O-galloyl-beta-D-glucose
-
from Saxifraga melanocentra
3-(2-[2-[2-(4-carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid
-
IC50: 0.0092 mM
3-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid methyl ester
-
IC50: 0.025 mM
3-(4-acetylphenoxy)propanoic acid
-
-
3-(4-hydroxy-3,5-diiodophenyl)-2-phenylpropanoic acid
-
-
3-(4-hydroxy-3,5-diiodophenyl)-3-phenylpropanoic acid
-
-
3-(4-hydroxy-3,5-diiodophenyl)propanoic acid
-
-
3-cyclohexyl-2,5-dioxo-12-oxa-1,4-diazatricyclo(11.5.3.016,20)-henicosa-13(21),14,16(20)-triene-18-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)aminooxalyl)butyl)amide
-
inhibitor adopts a donutlike conformation and has close contact to A156 methyl group of enzyme
3-[(2R,5S,8S)-8-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-5-cyclohexyl-3,6,14,18-tetraoxo-1,4,7,13-tetraazacyclooctadecan-2-yl]propanoic acid
-
-
3-[(3S,6R,17S)-17-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-3-cyclohexyl-2,5,8,11-tetraoxo-1,4,7,12-tetraazacycloheptadecan-6-yl]propanoic acid
-
-
3-[2-(2-Benzyloxycarbonylamino-3-methyl-pentanoylamino)-4-methyl-pentanoylamino]-5,5-difluoro-2-oxo-pentanoic acid
-
-
3-[2-(2-tert-Butoxycarbonylamino-4-carboxy-butyrylamino)-4-methyl-pentanoylamino]-5,5-difluoro-2-oxo-pentanoic acid
-
-
3-[2-(2-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-carboxy-butyrylamino)-3-cyclohexyl-propionylamino]-5,5-difluoro-2-oxo-pentanoic acid
-
-
3-[2-(3-tert-butyl-ureido)-2-indan-2-yl-acetyl]-6,6-dichloro-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide
-
-
3-[2-(3-tert-butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dichloro-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide
-
-
3-[2-[2-(2-Acetylamino-3,3-diphenyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-cyclohexyl-propionylamino]-5,5-difluoro-2-oxo-pentanoic acid
-
-
4-(2-aminoethyl)-benzenesulfonyl fluoride
-
0.45 mM, 50% inhibition
4-(2-[2-[2-(2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-4-methyl-pentanoylamino]-4,4-difluoro-but-2-enoylamino]-ethyl)-3-chloro-benzoic acid
-
highly specific
4-(2-[2-[2-(2-tert-Butoxycarbonylamino-4-carboxy-butyrylamino)-4-methyl-pentanoylamino]-4,4-difluoro-but-2-enoylamino]-ethyl)-3-chloro-benzoic acid
-
reversible competitive inhibitor, highly specific
4-(2-[2-[2-(4-carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-3-chloro-benzoic acid
-
IC50: 0.0007 mM
4-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-3-chloro-benzoic acid methyl ester
-
IC50: 0.0032 mM
4-(2-[2-[2-(4-carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid
-
IC50: 0.002 mM
4-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid methyl ester
-
IC50: 0.017 mM
4-(4-hydroxy-3,5-diiodophenyl)butanoic acid
-
-
4-(amidinophenyl)-methanesulfonyl fluoride
-
1.89 mM, 50% inhibition
4-(trifluoroacetyl)benzoic acid
-
-
4-Benzyloxycarbonylamino-4-[1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid
-
IC50: 0.04 mM
4-chloro-1H-indole-2-carboxylic acid
-
-
4-hydroxy-2-(4-hydroxybenzoyl)benzoic acid
-
-
4-hydroxy-3,5-diiodobenzoic acid
-
-
4-Isobutoxycarbonylamino-4-[1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid
-
IC50: 0.019 mM
4-methoxy-2-(4-methoxybenzoyl)benzoic acid
-
-
4-tert-Butoxycarbonylamino-4-(1-[1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-2-mercapto-ethylcarbamoyl]-3-methyl-butylcarbamoyl)-butyric acid
-
IC50: 0.0065 mM
4-tert-Butoxycarbonylamino-4-(1-[1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-3,3-difluoro-propenylcarbamoyl]-3-methyl-butylcarbamoyl)-butyric acid
-
-
4-tert-Butoxycarbonylamino-4-[1-(1-carboxy-2-mercapto-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid
-
IC50: above 0.2 mM
4-tert-Butoxycarbonylamino-4-[1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid
-
IC50: 0.027 mM
4-[(7R,9S,12R)-9-[(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-12-yl]cyclohexanecarboxylic acid
-
-
4-[1-(1-Benzylcarbamoyl-2-mercapto-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-4-tert-butoxycarbonylamino-butyric acid
-
IC50: above 0.2 mM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-(1-[1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-2-mercapto-ethylcarbamoyl]-2-cyclohexyl-ethylcarbamoyl)-butyric acid
-
IC50: 2 nM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[1-(1-benzylcarbamoyl-2-mercapto-ethylcarbamoyl)-2-cyclohexyl-ethylcarbamoyl]-butyric acid
-
IC50: 250 nM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-ethylcarbamoyl]-butyric acid
-
IC50: 7 nM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[1-(2-cyclohexyl-ethylcarbamoyl)-2-mercapto-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid
-
IC50: 1540 nM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[1-(indan-2-ylcarbamoyl)-2-mercapto-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid
-
IC50: 1700 nM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[2-mercapto-1-(2-phenyl-cyclopropylcarbamoyl)-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid
-
IC50: 1500 nM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[2-mercapto-1-(3-phenyl-propylcarbamoyl)-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid
-
IC50: 210 nM
4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[2-mercapto-1-(methyl-phenethyl-carbamoyl)-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid
-
IC50: 0.07 mM
4MeBu-P-norvaline-(CO)-GMSYS-NH2
-
CVS4440
5-bromo-1H-indole-2-carboxylic acid
-
-
5-bromo-2-(4-hydroxybenzoyl)benzoic acid
-
-
5-chloro-1-benzofuran-2-carboxylic acid
-
-
5-chloro-1H-indole-2-carboxylic acid
-
-
5-cyclohexyl-3,6-dioxo-11,16-dioxa-4,7-diazatricyclo(15.3.1.17,10)-docosa-1(21),17,19-triene-8-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)aminooxalyl)butyl)amide
-
-
5-fluoro-1H-indole-2-carboxylic acid
-
-
5-methoxy-1-benzothiophene-2-carboxylic acid
-
-
5-methoxy-1H-indole-2-carboxylic acid
-
-
5-methyl-1H-indole-2-carboxylic acid
-
-
6,6-dichloro-3-[2-cyclohexyl-2-(3-cyclohexyl-ureido)-acetyl]-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide
-
-
6-chloro-1H-indole-2-carboxylic acid
-
-
7-bromo-1H-indole-2-carboxylic acid
-
-
7-chloro-1H-indole-2-carboxylic acid
-
-
Ac-Asp-Glu-Leu-Ile-Cha-Cys-OH
-
-
Ac-DdIVPC-OH
-
0.04 mM, 50% inhibition
-
Ac-DvIVPC-OH
-
0.0075 mM, 50% inhibition
-
Ac-FASGKR-arginylaldehyde
-
competitive, 50% inhibition at about 0.001 mM
acetyl-3,3-diphenylalanine-beta-cyclohexylalanine-Cys-OH
-
0.3 mM, 50% inhibition
-
acetyl-Asp-(D-Glu)-(allyloxycarbonyl-L-lysine)-(L-cyclohexylalanine)-Cys-OH
-
-
acetyl-Asp-(D-Glu)-Leu-Ile-L-cyclohexylalanine-Cys-OH
-
-
acetyl-Asp-(D-Glu)-Tyr-Ile-L-cyclohexylalanine-Cys-OH
-
-
acetyl-Asp-(D-glutamine)-Leu-Ile-L-cyclohexylalanine-Cys-OH
-
-
acetyl-Asp-(D-homoglutamate)-Leu-Ile-L-cyclohexylalanine-Cys-OH
-
-
acetyl-Asp-(D-homoleucine)-Leu-Ile-(L-cyclohexylalanine)-Cys-OH
-
-
acetyl-Asp-D-(gamma-carboxyglutamic acid)-Leu-Ile-(beta-cyclohexylalanine)-Cys
-
-
acetyl-Asp-D-Glu-Leu-Ile-(beta-cyclohexylalanine)-Cys-(Me)Ala-Ser-His-Leu-NH2
-
IC50: 0.0006 mM, inhibitor is cleaved by NS3/4A protease
acetyl-Asp-Glu-(3,3-diphenylalanine)-Glu-(beta-cyclohexylalanine)-Cys
-
-
acetyl-Asp-Glu-(3,3-diphenylalanine)-Ile-(beta-cyclohexylalanine)-Cys
-
-
acetyl-Asp-Glu-(3,3-diphenylalanine)-Ile-(beta-cyclohexylalanine)-Cys-(Me)Ala-Ser-His-Leu-NH2
-
IC50: 0.0034 mM, inhibitor is cleaved by NS3/4A protease
acetyl-Asp-Glu-(diaminopropionyl)-(N-beta-dansyl)-Glu-(beta-cyclohexylalanine)-Cys-OH
-
-
acetyl-Asp-Glu-3,3-diphenylalanine-Glu-beta-cyclohexylalanine-Cys-OH
-
0.00005 mM, 50% inhibition
acetyl-Asp-Glu-3,3-diphenylalanine-Ile-beta-cyclohexylalanine-OH
-
0.046 mM, 50% inhibition
acetyl-Asp-Glu-Leu-Glu-(beta-cyclohexylalanine)-Cys
-
-
acetyl-Asp-Glu-Leu-Glu-beta-cyclohexylalanine-Cys-OH
-
0.0026 mM, 50% inhibition
acetyl-Asp-Glu-Leu-Ile-beta-cyclohexylalanine-Cys-OH
-
0.00006 mM, 50% inhibition
acetyl-Asp-Glu-Met-Glu-beta-cyclohexylalanine-Cys-OH
-
0.00035 mM, 50% inhibition
acetyl-Asp-Glu-Met-Glu-Glu-Cys
-
-
acetyl-Asp-Glu-Met-Glu-Glu-Cys-OH
-
0.001 mM, 50% inhibition
acetyl-Asp-Glu-Val-Val-Pro-boroAlg-OH
-
the inhibitor binds in an antiparrallel manner to beta-strand E2 and interacts with the unprimed sites of the substrate binding pocket. In the NS3/NS4 inhibitor complex, the inhibitor behaves like a reaction intermediate analog. In the absence of the cofactor, inhibitor binding is an order of magnitude weaker
acetyl-DEMEEC-OH
-
-
acetyl-DYPSPC-OH
-
-
acetyl-ECTTPC-OH
-
-
acetyl-EDVVCC-OH
-
-
acetyl-EEVVP-norvaline-(CO)-GMSYS-NH2
-
CVS4437
acetyl-EEVVP-norvaline-(CO)-phenethylamide
-
CVS4442
acetyl-Glu-3,3-diphenylalanine-Glu-beta-cyclohexyalanine-Cys-OH
-
0.0014 mM, 50% inhibition
acetyl-Glu-Asp-Val-Val-(alpha-aminobutyryl)-Cys-(1,2,3,4-tetrahydroisoquinoline-3-L-carboxyl)-Nle-Ser-Tyr-NH2
-
IC50: 0.0019 mM, inhibitor is cleaved by NS3/4A protease
acetyl-Glu-Asp-Val-Val-(alpha-aminobutyryl)-Cys-(Me)Ala-Nle-Ser-Tyr-NH2
-
IC50: 0.0035 mM, inhibitor is cleaved by NS3/4A protease
acetyl-Glu-Asp-Val-Val-Leu-Cys-(1,2,3,4-tetrahydroisoquinoline-3-L-carboxyl)-Nle-Ser-Tyr-NH2
-
IC50: 0.001 mM, inhibitor is cleaved by NS3/4A protease
acetyl-Glu-beta-cyclohexylalanine-Cys-OH
-
0.46 mM, 50% inhibition
acetyl-Glu-Leu-Glu-beta-cyclohexylalanine-Cys-OH
-
5 mM, 50% inhibition
acetyl-P-norvaline-(CO)-GMSYS-NH2
-
CVS4441
acetyl-QSVVCC-OH
-
-
acetyl-VVP-norvaline-(CO)-G-NH2
-
SCH212986
acetyl-VVP-norvaline-(CO)-S(Bzl)-NH2
-
SCH215426
alpha1-anitrypsin
-
-
-
antibody Fv fragment
-
specific for the HCV NS3 protease domain, IC50: 71.3 nM
-
Aprotinin
Asp-Glu-Leu-Ile-L-cyclohexylalanine-aminobutyryl-(Me)Ala-Ser-His-Leu
-
IC50: 5 mM
Asp-Glu-Leu-Ile-L-cyclohexylalanine-Cys-OH
-
IC50: 15 nM
Asp-Glu-Leu-Ile-L-cyclohexylalanine-Cys-Pro-L-cyclohexylalanine-Asp-Leu
-
IC50 below 0.2 nM
Asp-Glu-Leu-Ile-L-cyclohexylalanine-Cys-Pro-Nle-Ser-Leu
-
IC50: 10 nM
benzyl 1-([[(2S)-1-[(1R,5S)-2-[(4-amino-1-cyclopropyl-3,4-dioxobutan-2-yl)carbamoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]amino)cyclohexanecarboxylate
-
-
benzyloxycarbonyl-L-Ile-L-Leu-L-(difluoro)aminobutyric acid
-
-
BI201335
-
-
BILN 2061
BILN-2061
BILN2061
bis(4-aminophenyl)methanone
-
-
boceprevir
Bz-Ala-Lys-Arg-Arg-H
Bz-Arg-Arg-H
-
-
Bz-D-Nle-Lys-Arg-Arg-H
-
-
Bz-Lys-Arg-Arg-H
-
-
Bz-N-Me-Nle-Lys-Arg-Arg-H
-
-
Bz-Nle-Ala-Arg-Arg-H
Bz-Nle-D-Lys-Arg-Arg-H
-
-
Bz-Nle-Lys-Ala-Arg-H
Bz-Nle-Lys-Arg-(p-Cl)-Phe-H
-
-
Bz-Nle-Lys-Arg-(p-CN)-Phe-H
-
-
Bz-Nle-Lys-Arg-(p-guanidinyl)-Phe-H
-
-
Bz-Nle-Lys-Arg-(p-Ph)-Phe-H
-
-
Bz-Nle-Lys-Arg-Ala-H
Bz-Nle-Lys-Arg-Arg-H
Bz-Nle-Lys-Arg-D-Arg-H
-
-
Bz-Nle-Lys-Arg-His-H
-
-
Bz-Nle-Lys-Arg-Lys-H
Bz-Nle-Lys-Arg-Phe-H
Bz-Nle-Lys-Arg-Phg-H
-
-
Bz-Nle-Lys-Arg-Trp-H
-
-
Bz-Nle-Lys-Arg-Tyr-H
-
-
Bz-Nle-Lys-D-Arg-Arg-H
-
-
Bz-Nle-Lys-Lys(Z)-Arg-H
-
-
Bz-Nle-Lys-Lys-Arg-B(OH)2
-
-
Bz-Nle-Lys-Lys-Arg-H
Bz-Nle-Lys-N-Me-Arg-Arg-H
-
-
Bz-Nle-Lys-Phe-Arg-H
Bz-Nle-N-Me-Lys-Arg-Arg-H
-
-
Bz-Nle-Phe-Arg-Arg-H
Bz-Nle-Pro-Arg-Arg-H
-
-
Bz-Phe-Lys-Arg-Arg-H
chymostatin
-
0.71 mM, 50% inhibition
cyclopropanesulfonic acid [(Z)-(1R,4R,6S,15R,17R)-13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl]-amide
-
-
cyclopropanesulfonic acid [(Z)-(1R,4R,6S,15R,17R)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl]-amide
-
high potency, lacks the P4 substituent
cyclopropanesulfonic acid [(Z)-(1R,4R,6S,15R,17S)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0. 04,6]octadec-7-ene-4-carbonyl]-amide
-
-
cyclopropyl(4-methoxyphenyl)methanone
-
-
danoprevir
-
-
-
DCSTPC-OH
-
-
DDIVPC-OH
-
0.071 mM, 50% inhibition
deca-D-Arg-NH2
-
-
DEMEEC-NH2
-
-
DEMEEC-OH
-
-
dodeca-D-Arg-NH2
-
-
dodeka-D-Arg-NH2
-
-
EDVVAbuC-OH
-
-
EGTA
-
1.6 mM, 50% inhibition
fluorescein-L-Asp-D-Glu-L-Leu-L-Ile-L-beta-cyclohexylalanine-L-Cys-L-Pro-L-beta-cyclohexylalanine-L-Asp-L-Leu-NH2
-
i.e. PepInh-1, noncleavable decapeptidyl inhibitor
GS-9132
-
an acylthiourea with in vitro activity against Hepatitis C virus genotype 1, inhibits the formation of a functional replication complex. Reversible nephrotoxicity in clinical trials
hepta-D-Arg-NH2
-
-
hexa-D-Arg-NH2
-
-
IFN-alpha
-
-
-
iodoacetamide
-
0.26 mM, 50% inhibition
ITMN-191
ITMN-C
-
active site inhibitor of the NS3-4A protease
-
L-aminobutyric acid carboxylic acid
-
non-electrophilic and acidic compound
L-aminobutyric acid pentafluoroethyl ketone
-
electrophilic and non-acidic compound
L-norvaline carboxylic acid
-
non-electrophilic and acidic compound
L-norvaline ketotetrazole
-
electrophilic and acidic compound
L-norvaline pentafluoroethyl ketone
-
electrophilic and non-acidic compound
L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]carbonyl]-, 1,1-dimethylethyl ester
-
-
L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]carbonyl]-, methyl ester
-
-
L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]carbonyl]-, phenylmethyl ester
-
-
L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]sulfonyl]-, 1,1-dimethylethyl ester
-
-
methyl [5-(thiophen-2-ylcarbonyl)-1H-benzimidazol-2-yl]carbamate
-
inhibitor binding to Zn2+-free enzyme, dissociation constant 0.0019 mM, EC50 value 0.00003 mM
MK-7009
-
i.e. (1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,70.06,11]heptacosa-6,8,10-triene-24-carboxamide, potent and selective inhibitor of hepatitis C virus NS3/4A protease
N-(cyclohexylacetyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000037 mM
N-(cyclohexylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000009 mM
N-(cyclopentylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000005 mM
N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[[7-(acetylamino)-2-phenylquinolin-4-yl]oxy]-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-L-prolinamide
-
50% inhibition at 0.000029 mM
N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-([2-[2-(dimethylamino)-1,3-thiazol-4-yl]pyridin-4-yl]oxy)-L-prolinamide
-
-
N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000029 mM
N-(tert-butoxycarbonyl)-D-valyl-(4S)-N-(1-carboxy-2-ethenylcyclopropyl)-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-D-prolinamide
-
50% inhibition of processing of substrate SEAP-1 at 0.00026 mM
N-(tert-butylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
inhibitor derived from peptide DDIVPC applying rigidification of the peptide scaffold to the bioactive conformation
N-(tert-butylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000008 mM
N-([(1R,4R)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)-L-norvaline
-
-
N-([(1S,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)-L-norvaline
-
-
N-acetyl-L-alpha-aspartyl-L-alpha-glutamyl-b-phenyl-L-phenylalanyl-L-alpha-glutamyl-N-[1-(carboxycarbonyl)-3,3-difluoropropyl]-3-cyclohexyl-L-alaninamide
-
50% inhibition of processing of substrate SEAP-1 at 0.0067 mM
N-acetyl-L-alpha-aspartyl-L-alpha-glutamyl-beta-phenyl-L-phenylalanyl-L-alpha-glutamyl-3-cyclohexyl-L-alanine
-
1.17 mM, 50% inhibition
N-acetyl-L-alpha-aspartyl-N-[(1S)-2-[[(1S)-1-([(2S,4R)-2-[[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]carbamoyl]-4-[(2-phenylquinolin-4-yl)oxy]pyrrolidin-1-yl]carbonyl)-2,2-dimethylpropyl]amino]-1-cyclohexyl-2-oxoethyl]-D-alpha-glutamine
-
-
N-tosyl-Phe chloromethyl ketone
N-[(1S)-1-cyclohexyl-2-[[(2S)-1-(2-{[1-cyclopropyl-4-(cyclopropylamino)-3,4-dioxobutan-2-yl]carbamoyl]-1',3'-dihydrospiro[cyclobutane-1,2'-inden]-3-yl)-3,3-dimethyl-1-oxobutan-2-yl]amino}-2-oxoethyl]pyrazine-2-carboxamide
-
compound displays an EC50 of 0.8 microM against hepatitis C virus with no toxicity in Huh7 and Vero cells at concentration up to 10 and 100 microM, respectively. Unfortunately, overall cytotoxicity in cell based systems discourages further development
N-[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]-L-norvaline
-
-
N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000001 mM
N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000013 mM, no inhibition of human leukocyte elastase, cathepsin B
N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(6-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000041 mM
N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7,8-dimethoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000013 mM
N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000002 mM
N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(8-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000005 mM
N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[[2-(3-methoxyphenyl)quinolin-4-yl]oxy]-L-prolinamide
-
50% inhibition at 0.000010 mM
N-[(2S)-2-amino-2-cyclohexylacetyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000018 mM
N-[(2S)-2-cyclohexylpropanoyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000037 mM
N-[(2S)-2-[(N-acetyl-L-alpha-aspartyl-D-alpha-glutamyl)amino]-2-cyclohexylacetyl]-L-valyl-(4S)-4-(naphthalen-2-ylmethoxy)-D-prolyl-D-norvaline
-
-
N-[(cyclobutyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000024 mM
N-[(cyclohexyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000030 mM
N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-(methylideneamino)cyclopropyl]-4-hydroxy-L-prolinamide
-
-
N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide
-
50% inhibition at 0.000014 mM
N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4S)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-phenyl-L-prolinamide
-
-
N-[(cyclopentyloxy)carbonyl]-L-leucyl-(4R)-N-[(2S,3R)-2-carboxy-3-ethenylcyclopropyl]-4-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-L-prolinamide
-
-
N-[(cyclopentyloxy)carbonyl]-L-leucyl-(4R)-N-[(2S,3S)-2-ethenyl-3-phosphonocyclopropyl]-4-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-L-prolinamide
-
-
N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0(4,6)]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide
N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxy-quinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0]octadec-7-ene-4-carbonyl}-(1-methylcyclo propyl)-(1-methylcyclopropyl)sulfonamide
-
EC50 = 3.76 nM, non-cytotoxic (CC50 above 0.020 nM), and metabolically stable HCV inhibitor. Compound exhibits advantageous drug metabolism and pharmacokinetic properties in rat and dog, with a high liver exposure after oral administration, but limited heart exposure observed in rat
Nalpha-p-tosyl-Lys chloromethyl ketone
nona-D-Arg-NH2
-
reduces infection in primary neurons
octa-D-Arg-NH2
-
-
peptidyl-alpha ketoamides
-
-
-
phenylmethanesulfonyl fluoride
-
0.6 mM, 50% inhibition
RNA aptamer G9-I
-
noncompetitive inhibition, Arg161 as well Arg130 of the NS3 protease domain are essential for interaction with the G9-I aptamer
-
RNA aptamer G9-II
-
-
-
RNA aptamer G9-III
-
-
-
SCH 503034
-
-
SCH-503034
SCH217135
-
-
SCH217142
-
-
SCH217942
-
-
SCH6
-
active site inhibitor of the NS3-4A protease
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)-4'-[(2S)-2-[[(ethylamino)carbonyl]amino]-3-methyl-1-oxobutyl]hexahydro-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)-4'-[(2S)-2-[[[(cyclopropylmethyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]hexahydro-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)-4'-[(2S)-2-[[[[3-(dimethylamino)propyl]methylamino]carbonyl]amino]-3-methyl-1-oxobutyl]hexahydro-, (3'aR,6'aS)-
-
IC50: 0.00066 mM
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-2-[[[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-1-oxo-2-[[(2-propenylamino)carbonyl]amino]butyl]-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-1-oxo-2-[[(propylamino)carbonyl]amino]butyl]-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-1-oxo-2-[[[(2,2,2-trifluoroethyl)amino]carbonyl]amino]butyl]-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]-1-oxobutyl]-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-2-[[[[(1S)-2-methyl-1-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]propyl]amino]carbonyl]amino]-1-oxobutyl]-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4',4'''-[sulfonylbis[imino[(2S)-2-(1-methylethyl)-1-oxo-2,1-ethanediyl]]]bis[1'-(cyclopropylcarbonyl)hexahydro]-, (3'aR,3'''aR,6'aS,6'''aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-amino-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, monohydrochloride, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[(aminocarbonyl)amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[[(cyclohexylamino)carbonyl]amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[[(cyclopentylamino)carbonyl]amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-
-
-
Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[[(cyclopropylamino)carbonyl]amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-
-
-
STAT-C
-
-
-
Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid
Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid-COOH
Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid-NHSO2Ph
Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-2-aminovaleryl-NHSO2Ph
Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-aminobutyryl ((S)-2-amino-butanoyl)-C2F5
Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-Cys-OH
telaprevir
tert-butyl (1-cyclohexyl-2-[(3R)-3-[(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]pentyl)carbamoyl]-2-azabicyclo[2.2.1]hept-2-yl]-2-oxoethyl)carbamate
-
-
tert-butyl (1-[[(3R)-3-([1-(2-cyclobutylethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]carbonyl]-2,2-dimethylpropyl)carbamate
-
non-preferred name
tert-butyl (1-[[(3R)-3-([1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]carbonyl]-2,2-dimethylpropyl)carbamate
-
non-preferred name
tert-butyl (1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylate
-
-
tert-butyl (1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylate
-
-
tert-butyl (2S)-([N-[3-([[(3S,18S)-18-cyclohexyl-16,19-dioxo-3,4-dihydro-1H-7,2-(epoxyheptanoiminoethano)isoquinolin-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoate
-
-
tert-butyl (2S)-([N-[3-([[(3S,6S)-6-cyclohexyl-5,8-dioxo-4,7-diazabicyclo[14.3.1]icosa-1(20),16,18-trien-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoate
-
-
tert-butyl (2S)-([N-[3-([[(7R,9S,12S)-12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoate
-
-
tert-butyl (2S)-[([[3-([[(6S,8S,9R,10S,13S)-13-cyclohexyl-12,15-dioxo-2,7,23-trioxa-11,14-diazatetracyclo[15.3.1.16,9.18,11]tricosa-1(21),17,19-trien-10-yl]carbonyl]amino)-2-oxohexanoyl]amino]acetyl)amino](phenyl)ethanoate
-
-
tert-butyl [(2R,6S,12Z,14aR,16aS)-14a-[(cyclopropylsulfonyl)carbamoyl]-2-[(6-methoxyisoquinolin-1-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]carbamate
-
-
tert-butyl [1-([(3R)-3-[(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]-4-methylpentyl)carbamoyl]-2-azabicyclo[2.2.1]hept-2-yl]carbonyl)-2,2-dimethylpropyl]carbamate
-
non-preferred name
tert-butyl [1-([(3R)-3-[(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]pentyl)carbamoyl]-2-azabicyclo[2.2.1]hept-2-yl]carbonyl)-2,2-dimethylpropyl]carbamate
-
-
tert-butyl [1-cyclohexyl-2-[(3R)-3-([1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]-2-oxoethyl]carbamate
-
-
tert-butyl [2-[(3R)-3-([1-(cyclobutylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]-1-cyclohexyl-2-oxoethyl]carbamate
-
-
tert-butyloxacrybonyl-L-Glu-L-Leu-L-(difluoro)aminobutyric acid
-
-
TMC 435350
-
rapidly reversible inhibitor
TMC435
-
small-molecule reversible noncovalent inhibitor of the NS3/4A serine protease
trans-1,2-cyclohexanediamine-N,N,N',N'-tetraacetic acid
-
0.007 mM, 50% inhibition
undeca-D-Arg-NH2
-
-
vaniprevir
-
; MK-7009, i.e. (1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
VX-950
[(2R,5S,8S)-8-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-5-cyclohexyl-3,6,14,18-tetraoxo-1,4,7,13-tetraazacyclooctadecan-2-yl]acetic acid
-
-
[(2R,6R,12Z,13aS,14S,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl]phosphonic acid
-
-
[(3S,6R,17S)-17-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-3-cyclohexyl-2,5,8,11-tetraoxo-1,4,7,12-tetraazacycloheptadecan-6-yl]acetic acid
-
-
[(Z)-(1R,4R,6S,15R,17R)-4-cyclopropanesulfonylaminocarbonyl-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-en-13-yl]-carbamic acid tert-butyl ester
-
-
[1-(6-Ethyl-4-methanesulfonyl-5-oxo-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl)-2-methyl-propyl]-carbamic acid tert-butyl ester
-
IC50: 0.0005 mM
[1-[1-(2-Mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-2-methyl-propyl]-carbamic acid benzyl ester
-
IC50: 0.4 mM
[1-[2-(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethylcarbamoyl)-6,6-dichloro-3-aza-bicyclo[3.1.0]hexane-3-carbonyl]-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester
-
is the most promising of all the inhibitors. With tert-leucine as P3 residue, extremely potent with single digit nanomolar potency in enzymatic assay. Excellent selectivity against elastase. Bioavailability above 10% in rat, monkey, and dog
[2-[2-(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethylcarbamoyl)-6,6-dichloro-3-aza-bicyclo[3.1.0]hex-3-yl]-1-indan-2-yl-2-oxo-ethyl]-carbamic acid tert-butyl ester
-
-
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
4A cofactor peptide
-
-
-
DTT
-
required for maximal activity
glycerol
-
-
NS4A cofactor peptide
-
NS3-NS4A interaction consists of a high-affinity and a low-affinity interaction, contributing equally to the overall binding. By immobilizing NS3 alone or together with NS4A it is shown that inhibitors have a higher affinity for NS3 in the presence of NS4A. NS4A thus has a direct effect on the binding of inhibitors to NS3 and not only on catalysis
-
NS4A peptide
-
-
-
NS4A protein
-
NS4A serves as a cofactor for NS3 protease and helicase activities
-
Pep4AK
-
cofactor, peptide spanning the central hydrophobic core of the NS4A protein, with a three-lysine tag at the N-terminus
-
SP6EVC/S
-
inhibits by slow tight binding mechanism characteristics of serpin molecules, operating as a suicide substrate inhibitor. HCV-Pep4A is required for efficient formation of SDS-stable complex between NS3 protein and SP6EVC/S
-
Triton X-100
-
required for maximal activity
additional information
both auto-cleavage and NS3 protease activity show absolute requirement for cysteine residues 1123, 1125 and 1171 within NS3. Cysteine 922 (within NS2) is only required for NS2/3 auto-cleavage activity and histidine 1175 is only required for NS3 activity. Complete NS3 protease domain (including the C-terminal alpha-helix) is required for NS2/3 auto-cleavage, the activity of the NS3 protease is not essential
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0658
2-Naph-3Pya-Lys-Arg-p-nitroanilide
-
-
0.021
2-Naph-Cit-Lys-Arg-p-nitroanilide
-
-
0.1007
2-Naph-Cit-Orn-Arg-p-nitroanilide
-
-
0.048
2-Naph-hArg-Lys-Arg-p-nitroanilide
-
-
2.303
2-Naph-Lys-AcLys-Arg-p-nitroanilide
-
-
0.0434
2-Naph-Lys-Arg-Arg-p-nitroanilide
-
-
3.423
2-Naph-Lys-Cit-Arg-p-nitroanilide
-
-
0.0267
2-Naph-Lys-hArg-Arg-p-nitroanilide
-
-
0.0254 - 0.0977
2-Naph-Lys-Lys-Arg-p-nitroanilide
0.0368
2-Naph-Lys-Orn-Arg-p-nitroanilide
-
-
0.038
2-Naph-Orn-Lys-Arg-p-nitroanilide
-
-
0.0229
2-Naph-Orn-Orn-Arg-p-nitroanilide
-
-
0.00076 - 0.0292
7-methoxycoumarin-4-acetyl-DEMEECASHLPYK-(epsilon-NHCOCH3)
0.0436
7-methoxycoumarin-4-acetyl-EDASTPCSGSN-(4-nitro)Phe
-
presence of inhibitor peptide 4Apep21-34KK
0.053
9-fluorenylmethyloxycarbonyl-YQEFDEMEECASHLPYIEQG
-
-
0.0797
Ac-Aib-Lys-Lys-Arg-p-nitroanilide
-
-
0.0755
Ac-Aoc-Lys-Lys-Arg-p-nitroanilide
-
-
0.0227 - 0.03984
Ac-Asp-Glu-Lys(TAMRA)-Glu-Glu-AbuPSI[COO]-Ala-Ser-Lys(QSY-7)-amide
0.0699
Ac-Cha-Lys-Lys-Arg-p-nitroanilide
-
-
0.0819
Ac-Chg-Lys-Lys-Arg-p-nitroanilide
-
-
0.063 - 0.519
Ac-DEEMECASHLPYK-NH2
0.74
Ac-DPNRKR-4-nitroanilide
-
37C, pH 9.5
0.0012 - 0.0073
Ac-DTEDVVP(Nva)-O-4-phenylazophenyl ester
3.1
Ac-EMEECASHLP
-
-
0.45
Ac-FASGKR-4-nitroanilide
-
37C, pH 9.5
0.17 - 2.942
Ac-KPGLKR-4-nitroanilide
1.1 - 2.6
Ac-L-Asp-L-Glu-L-Asp-(EDANS)-L-Glu-L-Glu-alpha-aminobutyric acid-PSI[COO]-L-Ala-L-Ser-L-Lys-(DABCYL)-NH2
0.0887
Ac-Leu-3Pya-Lys-Arg-p-nitroanilide
-
-
0.2548
Ac-Leu-4Pya-Lys-Arg-p-nitroanilide
-
-
0.1413
Ac-Leu-aPhe-Lys-Arg-p-nitroanilide
-
-
0.2086
Ac-Leu-Cit-Lys-Arg-p-nitroanilide
-
-
0.199 - 0.879
Ac-Leu-Gln-Tyr-Thr-Lys-Arg-p-nitroanilide
0.0625
Ac-Leu-hArg-Lys-Arg-p-nitroanilide
-
-
0.0546 - 0.635
Ac-Leu-Lys-Lys-Arg-p-nitroanilide
0.2541
Ac-Leu-nPhe-Lys-Arg-p-nitroanilide
-
-
0.1055
Ac-Leu-Orn-Lys-Arg-p-nitroanilide
-
-
0.892
Ac-LQYTKR-4-nitroanilide
-
37C, pH 9.5
0.0807
Ac-Nle-Lys-Lys-Arg-p-nitroanilide
-
-
0.0673
Ac-Nva-Lys-Lys-Arg-p-nitroanilide
-
-
0.1342
Ac-Tbg-Lys-Lys-Arg-p-nitroanilide
-
-
0.15
Ac-YQEFDEMEECAS
-
-
0.11
Ac-YQEFDEMEECASH
-
-
0.12
Ac-YQEFDEMEECASHL
-
-
0.095
Ac-YQEFDEMEECASHLP
-
-
0.0028
acetyl-DEMEECASHLPYL-(epsilon-NHCOCH3)
-
presence of inhibitor peptide 4Apep21-34KK
0.0013 - 0.0066
anthraniloyl-DDIVP-Abu[C(O)-O] AMY(3-NO2)-TW-OH
0.0029 - 0.0042
anthranilyl-DDIVPAbu[C(O)-O]AMY(3-NO2)TW-OH
0.1422
Boc-Gly-Arg-Arg-AMC
-
-
0.041
Boc-RVRR-7-amido-4-methylcoumarin
-
pH 8.0, 18C
0.0146
Bz-norleucine-lysine-arginine-arginine-AMC
-
-
10
DEMEECASHLPYK
-
-
0.16 - 0.805
DEMEECSQHLPYI
0.019 - 0.08
DTEDVVCCSMSYTWTGK
0.0004 - 0.0054
EAGDDIVPCSMSYTWTGA-OH
0.0041
EAGDNIVPCSMSYTWTGA-OH
-
pH 7.5, wild-type enzyme
0.0038
EAGNDIVPCSMSYTWTGA-OH
-
pH 7.5, wild-type enzyme
0.0252
EAGNNIVPCSMSYTWTGA-OH
-
pH 7.5, wild-type enzyme
0.029 - 0.38
EDVV-4-aminobutyryl-CSMSY
0.053 - 0.552
EDVV-Abu-CSMSY
3.8
EDVVAbuCSMSY-NH2
-
-
1.01 - 1.08
Glu-Asp-Val-Val-4-aminobutyryl-Cys-p-nitroanilide
0.051
o-aminobenzoyl (Abz)-L-Asp-L-Asp-L-Ile-L-Val-L-Pro-L-Cys-L-Ser-L-Met-L-Ser-L-Tyr(3-NO2)-L-Thr-NH2
-
pH 7.3, 30C
0.043
Pyr-RTKR-7-amido-4-methylcoumarin
-
pH 8.0, 18C
0.146
Z-RR-7-amido-4-methylcoumarin
-
pH 8.0, 18C
additional information
additional information
-
-
-